Greenwich Free Cash Flow Yield vs Free Cash Flow Per Share Analysis

GLSI Stock

USD 14.25 0.32 2.20%

Greenwich Lifesciences financial indicator trend analysis is much more than just examining Greenwich Lifesciences latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Greenwich Lifesciences is a good investment. Please check the relationship between Greenwich Lifesciences Free Cash Flow Yield and its Free Cash Flow Per Share accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Greenwich Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.

Free Cash Flow Yield vs Free Cash Flow Per Share

Free Cash Flow Yield vs Free Cash Flow Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Greenwich Lifesciences Free Cash Flow Yield account and Free Cash Flow Per Share. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Greenwich Lifesciences' Free Cash Flow Yield and Free Cash Flow Per Share is 0.95. Overlapping area represents the amount of variation of Free Cash Flow Yield that can explain the historical movement of Free Cash Flow Per Share in the same time period over historical financial statements of Greenwich Lifesciences, assuming nothing else is changed. The correlation between historical values of Greenwich Lifesciences' Free Cash Flow Yield and Free Cash Flow Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Yield of Greenwich Lifesciences are associated (or correlated) with its Free Cash Flow Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Per Share has no effect on the direction of Free Cash Flow Yield i.e., Greenwich Lifesciences' Free Cash Flow Yield and Free Cash Flow Per Share go up and down completely randomly.

Correlation Coefficient

0.95

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Free Cash Flow Per Share

The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.

Most indicators from Greenwich Lifesciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Greenwich Lifesciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Greenwich Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.The Greenwich Lifesciences' current Enterprise Value is estimated to increase to about 240.3 M, while Selling General Administrative is projected to decrease to under 1.2 M.

	2021	2023	2024 (projected)
Reconciled Depreciation	3.6K	4.2K	4.0K
Total Operating Expenses	4.6M	9.3M	5.3M

Reconciled Depreciation Total Operating Expenses

Greenwich Lifesciences fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Intangible Assets	Common Stock	Short Long Term Debt Total	Current Deferred Revenue	Short Term Debt
Total Assets		-0.15	-0.21	0.95	-0.04	0.77	-1.0	-0.37	-0.23	1.0	-0.55	1.0	0.41	0.62	-0.7	0.84	-0.71	0.95	1.0	0.74	0.98	-0.55	0.76	-0.83	0.85	-0.83
Other Current Liab	-0.15		0.9	-0.22	0.27	-0.41	0.15	0.55	0.54	-0.15	0.55	-0.15	-0.65	-0.51	0.29	-0.4	0.3	-0.22	-0.15	-0.32	-0.2	0.55	-0.34	0.45	-0.44	0.45
Total Current Liabilities	-0.21	0.9		-0.23	0.33	-0.43	0.22	0.56	0.82	-0.22	0.54	-0.22	-0.5	-0.56	0.19	-0.41	0.2	-0.23	-0.22	-0.26	-0.26	0.54	-0.3	0.52	-0.5	0.52
Total Stockholder Equity	0.95	-0.22	-0.23		-0.28	0.91	-0.96	-0.6	-0.25	0.95	-0.75	0.95	0.63	0.77	-0.88	0.95	-0.88	1.0	0.95	0.89	0.98	-0.75	0.9	-0.92	0.94	-0.92
Other Liab	-0.04	0.27	0.33	-0.28		-0.58	0.06	0.83	0.58	-0.05	0.72	-0.05	-0.65	-0.76	0.47	-0.44	0.48	-0.28	-0.05	-0.46	-0.21	0.72	-0.45	0.43	-0.45	0.43
Net Tangible Assets	0.77	-0.41	-0.43	0.91	-0.58		-0.78	-0.87	-0.46	0.77	-0.95	0.77	0.83	0.92	-0.93	0.99	-0.93	0.91	0.77	0.95	0.84	-0.95	0.96	-0.98	0.98	-0.98
Net Debt	-1.0	0.15	0.22	-0.96	0.06	-0.78		0.38	0.24	-1.0	0.56	-1.0	-0.42	-0.63	0.71	-0.85	0.71	-0.96	-1.0	-0.74	-0.99	0.56	-0.77	0.84	-0.86	0.84
Retained Earnings	-0.37	0.55	0.56	-0.6	0.83	-0.87	0.38		0.58	-0.37	0.98	-0.37	-0.91	-0.9	0.79	-0.79	0.8	-0.6	-0.37	-0.8	-0.49	0.98	-0.8	0.8	-0.79	0.8
Accounts Payable	-0.23	0.54	0.82	-0.25	0.58	-0.46	0.24	0.58		-0.23	0.52	-0.23	-0.32	-0.66	0.12	-0.38	0.13	-0.25	-0.23	-0.2	-0.32	0.52	-0.24	0.5	-0.49	0.5
Cash	1.0	-0.15	-0.22	0.95	-0.05	0.77	-1.0	-0.37	-0.23		-0.55	1.0	0.41	0.62	-0.7	0.84	-0.71	0.95	1.0	0.74	0.98	-0.55	0.76	-0.83	0.85	-0.83
Non Current Assets Total	-0.55	0.55	0.54	-0.75	0.72	-0.95	0.56	0.98	0.52	-0.55		-0.55	-0.93	-0.92	0.88	-0.9	0.89	-0.75	-0.55	-0.9	-0.64	1.0	-0.91	0.9	-0.89	0.9
Cash And Short Term Investments	1.0	-0.15	-0.22	0.95	-0.05	0.77	-1.0	-0.37	-0.23	1.0	-0.55		0.41	0.62	-0.7	0.84	-0.71	0.95	1.0	0.74	0.98	-0.55	0.76	-0.83	0.85	-0.83
Common Stock Total Equity	0.41	-0.65	-0.5	0.63	-0.65	0.83	-0.42	-0.91	-0.32	0.41	-0.93	0.41		0.8	-0.86	0.8	-0.86	0.63	0.41	0.85	0.5	-0.93	0.84	-0.76	0.75	-0.76
Common Stock Shares Outstanding	0.62	-0.51	-0.56	0.77	-0.76	0.92	-0.63	-0.9	-0.66	0.62	-0.92	0.62	0.8		-0.77	0.85	-0.77	0.77	0.62	0.77	0.74	-0.92	0.79	-0.86	0.89	-0.86
Non Current Liabilities Total	-0.7	0.29	0.19	-0.88	0.47	-0.93	0.71	0.79	0.12	-0.7	0.88	-0.7	-0.86	-0.77		-0.94	1.0	-0.88	-0.7	-0.99	-0.75	0.88	-0.98	0.87	-0.88	0.87
Other Stockholder Equity	0.84	-0.4	-0.41	0.95	-0.44	0.99	-0.85	-0.79	-0.38	0.84	-0.9	0.84	0.8	0.85	-0.94		-0.94	0.95	0.84	0.96	0.88	-0.9	0.98	-0.99	0.98	-0.99
Total Liab	-0.71	0.3	0.2	-0.88	0.48	-0.93	0.71	0.8	0.13	-0.71	0.89	-0.71	-0.86	-0.77	1.0	-0.94		-0.88	-0.71	-0.99	-0.75	0.89	-0.98	0.88	-0.88	0.88
Net Invested Capital	0.95	-0.22	-0.23	1.0	-0.28	0.91	-0.96	-0.6	-0.25	0.95	-0.75	0.95	0.63	0.77	-0.88	0.95	-0.88		0.95	0.89	0.98	-0.75	0.9	-0.92	0.94	-0.92
Total Current Assets	1.0	-0.15	-0.22	0.95	-0.05	0.77	-1.0	-0.37	-0.23	1.0	-0.55	1.0	0.41	0.62	-0.7	0.84	-0.71	0.95		0.74	0.98	-0.55	0.76	-0.83	0.85	-0.83
Capital Stock	0.74	-0.32	-0.26	0.89	-0.46	0.95	-0.74	-0.8	-0.2	0.74	-0.9	0.74	0.85	0.77	-0.99	0.96	-0.99	0.89	0.74		0.77	-0.9	1.0	-0.92	0.91	-0.92
Net Working Capital	0.98	-0.2	-0.26	0.98	-0.21	0.84	-0.99	-0.49	-0.32	0.98	-0.64	0.98	0.5	0.74	-0.75	0.88	-0.75	0.98	0.98	0.77		-0.64	0.8	-0.87	0.9	-0.87
Intangible Assets	-0.55	0.55	0.54	-0.75	0.72	-0.95	0.56	0.98	0.52	-0.55	1.0	-0.55	-0.93	-0.92	0.88	-0.9	0.89	-0.75	-0.55	-0.9	-0.64		-0.91	0.9	-0.89	0.9
Common Stock	0.76	-0.34	-0.3	0.9	-0.45	0.96	-0.77	-0.8	-0.24	0.76	-0.91	0.76	0.84	0.79	-0.98	0.98	-0.98	0.9	0.76	1.0	0.8	-0.91		-0.94	0.93	-0.94
Short Long Term Debt Total	-0.83	0.45	0.52	-0.92	0.43	-0.98	0.84	0.8	0.5	-0.83	0.9	-0.83	-0.76	-0.86	0.87	-0.99	0.88	-0.92	-0.83	-0.92	-0.87	0.9	-0.94		-0.99	1.0
Current Deferred Revenue	0.85	-0.44	-0.5	0.94	-0.45	0.98	-0.86	-0.79	-0.49	0.85	-0.89	0.85	0.75	0.89	-0.88	0.98	-0.88	0.94	0.85	0.91	0.9	-0.89	0.93	-0.99		-0.99
Short Term Debt	-0.83	0.45	0.52	-0.92	0.43	-0.98	0.84	0.8	0.5	-0.83	0.9	-0.83	-0.76	-0.86	0.87	-0.99	0.88	-0.92	-0.83	-0.92	-0.87	0.9	-0.94	1.0	-0.99

Click cells to compare fundamentals

Greenwich Lifesciences Account Relationship Matchups

Greenwich Lifesciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	26.7K	28.7M	27.2M	13.5M	7.0M	6.6M
Other Current Liab	646.8K	770.3K	164.3K	42.1K	258.9K	311.1K
Total Current Liabilities	1.4M	1.0M	385.2K	262.9K	294.4K	545.8K
Total Stockholder Equity	(1.4M)	27.6M	26.8M	13.2M	6.7M	11.5M
Net Debt	(6.2K)	(28.7M)	(27.2M)	(13.5M)	(7.0M)	(7.3M)
Retained Earnings	(27.2M)	(29.1M)	(33.6M)	(41.5M)	(50.4M)	(52.9M)
Cash	6.8K	28.7M	27.2M	13.5M	7.0M	6.6M
Non Current Assets Total	19.8K	16.2K	12.6K	9.0K	5.4K	5.1K
Cash And Short Term Investments	6.8K	28.7M	27.2M	13.5M	7.0M	6.6M
Common Stock Shares Outstanding	11.7M	12.7M	12.9M	12.9M	12.8M	13.8M
Liabilities And Stockholders Equity	26.7K	28.7M	27.2M	13.5M	7.0M	6.6M
Other Stockholder Equity	25.9M	56.7M	60.5M	54.7M	57.1M	49.2M
Total Liab	1.4M	1.0M	385.2K	262.9K	294.4K	279.7K
Net Invested Capital	(1.4M)	27.6M	26.8M	13.2M	6.7M	11.5M
Total Current Assets	6.8K	28.7M	27.2M	13.5M	7.0M	6.6M
Capital Stock	10.4K	12.7K	13.1K	12.8K	14.8K	11.8K
Net Working Capital	(1.4M)	27.6M	26.8M	13.2M	6.7M	13.3M
Intangible Assets	19.8K	16.2K	12.6K	9.0K	5.4K	5.1K
Common Stock	8.5K	12.7K	13.1K	12.8K	14.8K	11.0K

Currently Active Assets on Macroaxis

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft
HBI	Hanesbrands
STLD	Steel Dynamics

When determining whether Greenwich Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Greenwich Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Greenwich Lifesciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Greenwich Lifesciences Stock:

How To Invest In Greenwich

Details

Is Greenwich Stock a good investment?

Details

What is Greenwich Lifesciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Greenwich Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.

You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.81)

Return On Assets

(0.72)

Return On Equity

(1.24)

The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Greenwich Free Cash Flow Yield vs Free Cash Flow Per Share Analysis

Free Cash Flow Yield vs Free Cash Flow Per Share

Free Cash Flow Yield vs Free Cash Flow Per Share Correlation Analysis

Correlation Coefficient

Free Cash Flow Yield

Free Cash Flow Per Share

Greenwich Lifesciences fundamental ratios Correlations

Greenwich Lifesciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Greenwich Lifesciences fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash

Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Assets
Short Term Debt	- 0.99	Current Deferred Revenue
Current Deferred Revenue	- 0.99	Short Long Term Debt Total